Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Medical Genetics · Mitochondrial disease associated with the m.3243A>G variant

Understanding Your Mitochondrial Diagnosis

At a Glance

The m.3243A>G mitochondrial DNA variant can affect the inner ear and heart at different times and with varying severity. Regular hearing tests, ECGs, and heart imaging help detect changes early, while treatment is tailored to the findings.

Receiving a diagnosis involving the m.3243A>G variant can feel overwhelming, especially since it affects the very parts of your cells—the mitochondria—that produce energy [1]. This specific genetic change is the most common cause of mitochondrial disease in adults [2]. Because mitochondria are found in nearly every cell in your body, this condition can affect multiple systems, most notably your heart and your hearing [3].

Understanding the Rarity and Frequency

While the m.3243A>G variant itself may be present in as many as 1 in 400 people, only a small fraction of these individuals will develop a clinical disease that requires medical attention [4][3]. In some regions, the minimum prevalence of diagnosed disease is estimated at approximately 4.2 per 100,000 adults [1].

Because the condition is rare, many local doctors may not have encountered it before. Your care often requires a team approach involving specialists in genetics, cardiology, and audiology who are familiar with mitochondrial medicine [5].

The Role of Heteroplasmy

One of the most important concepts to understand is heteroplasmy. Unlike most genetic traits where every cell has the same DNA, mitochondrial variants are often “mixed” [3]. You have a population of healthy mitochondria and a population with the m.3243A>G variant living side-by-side in your cells.

The proportion of variant mitochondria—your heteroplasmy level—can vary between different tissues, such as your blood, skin, or urine [6][7]. Higher levels in blood are generally associated with a higher risk of symptoms, but it is not a perfect predictor [3]. Interestingly, research shows the level of this variant in the blood typically decreases as you age (by a cohort average of about 2.3% each year), which is why doctors may prefer testing urine or other tissues [8][6]. A low blood result does not necessarily represent the mutation level in your heart or inner ear and cannot be used alone to predict prognosis.

How It Affects Your Hearing

Sensorineural hearing loss (hearing loss caused by damage to the inner ear or the nerve pathways) is one of the most frequent symptoms of this diagnosis [2]. It is often “post-lingual,” meaning it develops after you have already learned to speak [9].

  • Timing: Hearing loss often begins in early adulthood, with one study reporting an average onset age of 26 [9]. In other cases, it may not appear until your 30s or 40s [7].
  • Progression: The hearing loss is typically bilateral (affecting both ears) and can progress over time [10]. In some individuals, the decline can be rapid, while in others, it remains stable for many years [10].
  • Broad Effects: Beyond simple volume, you may find it difficult to understand speech in noisy environments or have trouble locating where a sound is coming from [11].

How It Affects Your Heart

The heart requires a massive amount of energy to pump, making it sensitive to mitochondrial changes. Cardiomyopathy (a disease of the heart muscle) can take several forms in people with this variant:

  • Hypertrophic Cardiomyopathy (HCM): The heart muscle becomes abnormally thick. This primarily makes the heart stiffer and less efficient at relaxing and filling with blood, even if the pumping strength initially remains normal [12].
  • Dilated Cardiomyopathy (DCM): The heart muscle becomes thin and weakened [12].
  • Conduction Issues: The electrical signals that tell your heart when to beat can become disrupted, leading to arrhythmias (irregular heartbeats) [12][13].

Cardiomyopathy often develops in adulthood, though it can appear in childhood [14]. Adult-onset m.3243A>G disease can still involve serious cardiomyopathy or conduction disease. Your serial ECG, imaging, and rhythm monitor results matter much more than your age at onset [14].

No Single Timeline

There is no “standard” order for how these symptoms appear. This unpredictability is a hallmark of mitochondrial disease.

  • Hearing First: Many patients experience hearing loss years or even decades before any heart issues are detected [15].
  • Heart First: In some cases, a heart rhythm issue or muscle thickening is the first sign of the condition.
  • Simultaneous: Others may discover both issues at the same time during a comprehensive medical evaluation.

Because there is no fixed sequence, lifelong monitoring is the standard of care. This usually involves regular hearing tests (audiometry) and heart screenings, including ECGs (to check electrical activity) and echocardiograms (ultrasounds to check heart structure) [12][16]. In some cases, a Cardiac MRI may be used conditionally to look for subtle scarring or changes that an ultrasound might miss [17].

Managing Your Health

While there is currently no cure for mitochondrial disease, your care team focuses on managing symptoms and preventing complications. This includes:

  • Regular Screenings: Even if you feel well, routine heart and hearing checks can catch changes early when they are most manageable [12].
  • Symptom Management: Using hearing aids or cochlear implants for hearing loss, and standard heart medications (like ACE inhibitors or beta-blockers) depending on your specific cardiac phenotype and guideline-based indications [16][5].
  • Individualized Care: Because this variant is also linked to diabetes (MIDD) and other issues, your doctor will tailor your monitoring based on your specific symptoms and history [18][5].

Common questions in this guide

What does an m.3243A>G diagnosis mean?
It means testing found a specific change in mitochondrial DNA. This change can reduce energy production in cells and may affect several organs, especially the heart and inner ear. The effects and timing vary widely between people.
What is heteroplasmy, and why does the test tissue matter?
Heteroplasmy is the mixture of mitochondria with and without the m.3243A>G variant in the same person. The proportion can differ among blood, urine, skin, and other tissues, and blood levels often fall with age. A low blood result therefore cannot by itself predict how the heart or hearing will be affected.
How can m.3243A>G affect hearing?
It can cause post-lingual sensorineural hearing loss, meaning inner-ear or related nerve damage after speech develops. Hearing loss is often in both ears and may progress quickly, slowly, or remain stable for years. People may also have trouble understanding speech in background noise or locating sounds.
What heart problems can occur with this mitochondrial variant?
It can be associated with hypertrophic cardiomyopathy, in which the heart muscle thickens, or dilated cardiomyopathy, in which it becomes thin and weakened. It can also disrupt the heart’s electrical signals and cause arrhythmias. ECGs, echocardiograms, rhythm monitoring, and sometimes cardiac MRI help clinicians look for these changes.
Why are regular heart and hearing checks needed if I feel well?
Mitochondrial heart and hearing problems may develop at different times, and some people have few symptoms at first. Regular audiometry, ECGs, and echocardiograms can identify changes early; cardiac MRI may be used when more detailed heart imaging is needed. Your care team will determine the testing schedule for you.
Is there a cure for m.3243A>G mitochondrial disease?
There is currently no cure, so care focuses on monitoring, symptom management, and preventing complications. Hearing aids or cochlear implants may help hearing loss, while ACE inhibitors or beta-blockers may be used for certain heart findings when clinically appropriate. Treatment is individualized to your symptoms, heart findings, and medical history.
Could this diagnosis affect my risk of diabetes?
The m.3243A>G variant is also linked with diabetes, including the mitochondrial diabetes pattern called MIDD, as well as other non-cardiac symptoms. Your clinician can decide whether diabetes testing and additional monitoring are appropriate based on your symptoms, family history, and test results.

Get notified when new evidence is published on Mitochondrial DNA-related cardiomyopathy and hearing loss.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Incidence and prevalence of mtDNA-related adult mitochondrial disease in Southwest Finland, 2009-2022: an observational, population-based study.

    Martikainen MH, Majamaa K

    BMJ neurology open 2024; (6(1)):e000546 doi:10.1136/bmjno-2023-000546.

    PMID: 38361968
  2. 2

    Neurological manifestations in adult patients with the m.3243A>G variant in mitochondrial DNA.

    Majamaa K, Kärppä M, Moilanen JS

    BMJ neurology open 2024; (6(2)):e000825 doi:10.1136/bmjno-2024-000825.

    PMID: 39324021
  3. 3

    Penetrance and expressivity of mitochondrial variants in a large clinically unselected population.

    Cannon SJ, Hall T, Hawkes G, et al.

    Human molecular genetics 2024; (33(5)):465-474 doi:10.1093/hmg/ddad194.

    PMID: 37988592
  4. 4

    Sudden adult death syndrome in m.3243A>G-related mitochondrial disease: an unrecognized clinical entity in young, asymptomatic adults.

    Ng YS, Grady JP, Lax NZ, et al.

    European heart journal 2016; (37(32)):2552-9 doi:10.1093/eurheartj/ehv306.

    PMID: 26188002
  5. 5

    Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society.

    Parikh S, Goldstein A, Karaa A, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2017; (19(12)) doi:10.1038/gim.2017.107.

    PMID: 28749475
  6. 6

    Non-invasive urinary heteroplasmy screening outperforms blood testing for certain mitochondrial DNA variants in mitochondrial disease patients.

    Okazaki A, Yatsuka Y, Fushimi T, et al.

    Molecular genetics and metabolism 2026; (148(4)):110198 doi:10.1016/j.ymgme.2026.110198.

    PMID: 42424991
  7. 7

    Screening for Maternally Inherited Diabetes and Deafness in Large Cohorts of Hearing Impaired and Diabetic Patients.

    Varga L, Borecka S, Skopkova M, et al.

    Ear and hearing 2026; (47(3)):863-876 doi:10.1097/AUD.0000000000001780.

    PMID: 41664274
  8. 8

    mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease.

    Grady JP, Pickett SJ, Ng YS, et al.

    EMBO molecular medicine 2018; (10(6)) doi:10.15252/emmm.201708262.

    PMID: 29735722
  9. 9

    Clinical characteristics and hearing impairment in carriers of the m.3243 A > G variant.

    Uehara N, Fujita T, Uehara K, et al.

    Journal of human genetics 2026; (71(3)):145-149 doi:10.1038/s10038-025-01412-3.

    PMID: 41131326
  10. 10

    Long-Term Progression and Rapid Decline in Hearing Loss in Patients with a Point Mutation at Nucleotide 3243 of the Mitochondrial DNA.

    Sakata A, Kashio A, Koyama H, et al.

    Life (Basel, Switzerland) 2022; (12(4)) doi:10.3390/life12040543.

    PMID: 35455034
  11. 11

    Auditory and vestibular function in mitochondrial patients harbouring the m.3243A>G variant.

    Stefanetti RJ, Newman J, Blain AP, et al.

    Brain communications 2024; (6(6)):fcae361 doi:10.1093/braincomms/fcae361.

    PMID: 39497799
  12. 12

    The heart in m.3243A>G carriers.

    Finsterer J, Zarrouk-Mahjoub S

    Herz 2020; (45(4)):356-361 doi:10.1007/s00059-018-4739-6.

    PMID: 30128910
  13. 13

    Systematic review and meta-analysis of cardiac involvement in mitochondrial myopathy.

    Quadir A, Pontifex CS, Lee Robertson H, et al.

    Neurology. Genetics 2019; (5(4)):e339 doi:10.1212/NXG.0000000000000339.

    PMID: 31403078
  14. 14

    Clinical profile and outcome of cardiac involvement in MELAS syndrome.

    Brambilla A, Favilli S, Olivotto I, et al.

    International journal of cardiology 2019; (276()):14-19 doi:10.1016/j.ijcard.2018.10.051.

    PMID: 30482630
  15. 15

    Bilateral deafness, diabetes, and different types of cardiomyopathy in family members with m.3243A > g mutation: a case report.

    Seiler F, Ruile P, Moser M, Helbing T

    European heart journal. Case reports 2023; (7(2)):ytad073 doi:10.1093/ehjcr/ytad073.

    PMID: 36865084
  16. 16

    Audiological manifestations in mitochondrial encephalomyopathy lactic acidosis and stroke like episodes (MELAS) syndrome.

    Vandana VP, Bindu PS, Sonam K, et al.

    Clinical neurology and neurosurgery 2016; (148()):17-21.

    PMID: 27359089
  17. 17

    Cardiac manifestations in adult MELAS syndrome (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome)- a cross-sectional study.

    Stoevesandt D, Schlitt A, Röntgen P, Kraya T

    Orphanet journal of rare diseases 2025; (20(1)):62 doi:10.1186/s13023-025-03534-5.

    PMID: 39930534
  18. 18

    The West of Scotland Cohort of Mitochondrial Individuals with the m.3243A>G Variant: Variations in Phenotypes and Predictors of Disease Severity.

    Saunders C, Longman C, Gorman G, et al.

    Journal of neuromuscular diseases 2024; (11(1)):179-189 doi:10.3233/JND-230166.

    PMID: 38108361

This page is for informational purposes only and does not constitute medical advice about m.3243A>G mitochondrial disease. Your genetics, cardiology, and audiology teams should interpret your test results and tailor heart and hearing monitoring to you.